UCB (OTCMKTS:UCBJF) Stock Price Down 5.8% – Here’s What Happened

UCB SA (OTCMKTS:UCBJF) shares were down 5.8% during mid-day trading on Thursday . The stock traded as low as $289.00 and last traded at $289.00. Approximately 116 shares were traded during trading, a decline of 85% from the average daily volume of 783 shares. The stock had previously closed at $306.94.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on UCBJF shares. Wolfe Research began coverage on shares of UCB in a research note on Monday, February 23rd. They set an “outperform” rating on the stock. The Goldman Sachs Group restated a “buy” rating on shares of UCB in a report on Monday, February 16th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy”.

UCB Stock Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The stock’s 50-day moving average is $294.32 and its two-hundred day moving average is $297.16.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.